Grants and Contributions
About this information
In June 2016, as part of the Open Government Action Plan, the Treasury Board of Canada Secretariat (TBS) committed to increasing the transparency and usefulness of grants and contribution data and subsequently launched the Guidelines on the Reporting of Grants and Contributions Awards, effective April 1, 2018.
The rules and principles governing government grants and contributions are outlined in the Treasury Board Policy on Transfer Payments. Transfer payments are transfers of money, goods, services or assets made from an appropriation to individuals, organizations or other levels of government, without the federal government directly receiving goods or services in return, but which may require the recipient to provide a report or other information subsequent to receiving payment. These expenditures are reported in the Public Accounts of Canada. The major types of transfer payments are grants, contributions and \'other transfer payments\'.
Included in this category, but not to be reported under proactive disclosure of awards, are (1) transfers to other levels of government such as Equalization payments as well as Canada Health and Social Transfer payments. (2) Grants and contributions reallocated or otherwise redistributed by the recipient to third parties; and (3) information that would normally be withheld under the Access to Information Act and the Privacy Act.
$400,000.00
Jan 1, 2020
For-profit organization
panKiller: Implementing a dual safety switch (suicide genes) in human pluripotent stem cells
947179
panKiller is an extension of panCELLa's proprietary FailSafe. panKiller is covered by the same patent as FailSafe: TOOLS AND METHODS FOR USING CELL DIVISION LOCI TO CONTROL PROLIFERATION OF CELLS. The patent was filed globally in most industrialized nations. panKiller involves the integration of a two-step safety switch. The first step utilizes FailSafe while the next step will utilize a second safety switch, panKiller, in order to eliminate all the therapeutic cells once therapy is complete and the therapeutic cells are no longer required. panKiller will link a suicide gene (iCaspase9) to a gene essential for cell survival (EEF2) in human induced pluripotent stem cells. There are currently no two-step safety switches on the market.